Compare LND & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | OABI |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Brazil | United States |
| Employees | N/A | 89 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.6M | 225.9M |
| IPO Year | N/A | N/A |
| Metric | LND | OABI |
|---|---|---|
| Price | $4.05 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 131.8K | ★ 285.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.65 | $52.42 |
| Revenue Next Year | $6.42 | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $1.22 |
| 52 Week High | $4.45 | $2.22 |
| Indicator | LND | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 34.43 |
| Support Level | $3.58 | $1.51 |
| Resistance Level | $4.39 | $1.75 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 36.22 | 16.47 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.